News

Keytruda (pembrolizumab), an anti-PD-1 therapy, works by enhancing the ability of the body’s immune system to identify and fight tumour cells. It is a humanised monoclonal antibody that

The addition of Calquence to best supportive care (BSC) has failed to increase the proportion of patients who remained alive and free of respiratory failure. Calquence, the next-generation

“We thank the FDA for expediting our new Investigational New Drug (IND) application and approving this clinical trial to evaluate Camostat as a treatment for patients suffering from

The interim analysis showed that Sputnik V vaccine has shown an efficacy rate of 92% after the second dose in the patients. Sputnik V vaccine is based on

NAVIGATOR met the primary endpoint with tezepelumab added to standard of care (SoC) demonstrating a statistically significant and clinically meaningful1 reduction in the annualized asthma exacerbation rate (AAER) over

SCD, which is a common single-gene disorder, is estimated to affect over 70,000 in the EU-27 and up to 100,000 people in the US. The status was provided

The trial, being conducted at Hoag Hospital in Newport Beach, California, enrolled 20 volunteers across two dose levels and the subject screening for the Phase I expansion cohort

According to BlueWillow Biologics, the preclinical research shown that the company’s nasal vaccine adjuvant combined with Medigen’s S-2P spike protein enabled to significantly neutralise antibody response. The research

Following a pre-specified interim analysis, the DSMB indicated that cabotegravir met the primary objective of demonstrating superiority when compared to the current standard of care for women, daily